News

June 30, 2021

CureLab Oncology Submits Patent for COVID Therapeutic Ahead of Phase I Clinical Trials

CureLab Oncology intends to determine whether its Elenagen DNA vaccine can be used to reduce severity, mortality and life-threatening post-COVID complications.
March 15, 2021

CureLab Oncology adds Hong Kong to expanding scope of patent protection

Patent registration in Hong Kong paves the way to establishing business operations in PRC
January 22, 2021

Curelab Veterinary Launches in Animal Health Sector, Leveraging Technology Licensed from CureLab Oncology

Based on a scientifically solid proof of concept in dogs and cats, a licensed international IP portfolio, and a comprehensive scientific advisory board that includes key opinion leaders and experienced management, CureLab Veterinary intends to raise initial financing through a crowdfunding and to become profitable within 36 months of raising funds.
November 10, 2020
CureLab_EU

CureLab Oncology Establishes Operations in Europe

CureLab is expanding its global presence with a new office from which it will base operations in the European Union; Ricarda Cramer joins as business development director
October 21, 2020

CureLab Oncology Establishes Operations in the Gulf Region

CureLab is expanding its global presence with a new office in the Gulf Cooperation Council (GCC) region; CureLab's partners in the region will test the efficacy of the company's DNA-based products against cancers and non-cancerous diseases of chronic inflammation
October 14, 2020

CureLab Oncology Appoints The Honorable David J. Shulkin, M.D. to its Scientific Advisory Board

Former US Secretary of Veterans Affairs and internationally known healthcare industry leader to advise on partnerships for upcoming clinical trials and market entry strategy for CureLab’s Elenagen cancer therapy
October 5, 2020

CureLab Oncology Receives Pre-IND Response from FDA Regarding Planned Trial for Triple Negative Breast Cancer

Feedback from FDA was constructive and includes recommendations to test cumulative toxicity and clinical benefits progression; this has led the company to consider a shorter trial design for Phase II.
April 29, 2020

CureLab Oncology’s Dr. Alex Shneider Publishes Paper: Can Melatonin Reduce the Severity of COVID-19?

Melatonin may prevent the development of severe disease symptoms in coronavirus patients, reduce the severity of their symptoms, and/or reduce the immuno-pathology of coronavirus infection on patients’ health after the active phase of the infection is over
January 20, 2020
A Disruptive Approach to Oncology Therapy Development

A Disruptive Approach to Oncology Therapy Development

CureLab Oncology CEO Alex Shneider’s lament is a biopharma industry that exhibits little appetite for those discoveries made while coloring outside the lines
March 3, 2023

CureLab Receives $3M from Prominent Biotech Investor Dr. John Ballantyne

Ballantyne is the co-founder and former chief scientific officer of Aldevron, a leading manufacturer of plasmids and other biologicals
November 5, 2022

Biotech Internship Opportunity! FDA/USDA liaison

CureLab Oncology and CureLab Veterinary are looking for interns to work with our FDA/USDA team on regulatory activities
September 10, 2022

ESMO 2022: Interim Results for Treatment of Platinum-Resistant Ovarian Cancer with p62 Plasmid DNA Show Statistically Significant Changes in Progression-Free Survival

While the disease has progressed in all patients receiving standard of care, it did not progress in 40% of the patients receiving standard chemotherapy together with the experimental drug, Elenagen — and for half of the patients in the group, Elenagen has increased the time to disease progression by more than 2.5 times
May 3, 2022

CureLab Oncology Secures Patent Protection for P62 Plasmid Therapeutic in South Korea

Patent registration in South Korea opens door to commercial agreements in an enormous market with high economic potential for CureLab